DR-TB Coordinator | Knowledge Base

Interim Treatment Outcomes of DR-TB Cases

H5Content

Severity Criteria for Reporting ADRs

H5Content

Causality Assessment: WHO-UMC [UPSALA Monitoring Centre] Causality Categories for ADR Reporting

H5Content

Causality Assessment for ADR Reporting

H5Content

Methods for Pharmacovigilance Activity Reporting [aDSM]

H5Content

Adverse Drug Events: H Mono/Poly DR-TB Regimen

H5Content

Replacement Sequence in the H Mono/Poly DR-TB

H5Content

Regimen, Duration and Dosage for Isoniazid [H] Mono/Poly DR-TB Regimen

H5Content

Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation

H5Content

Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen

H5Content

Subscribe to DR-TB Coordinator